BiotechTube

Elinzanetant (BAY3427080) + Rosuvastatin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Conditions

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Trial Timeline

May 26, 2021 → Sep 29, 2021

NCT ID
NCT04889287

About Elinzanetant (BAY3427080) + Rosuvastatin

Elinzanetant (BAY3427080) + Rosuvastatin is a phase 1 stage product being developed by Bayer for Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men. The current trial status is completed. This product is registered under clinical trial identifier NCT04889287. Target conditions include Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men.

What happened to similar drugs?

1 of 14 similar drugs in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men were approved

Approved (1) Terminated (0) Active (13)
✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
🔄fezolinetant + placeboAstellas PharmaPhase 3
🔄DVS-233 SRPfizerPhase 3
🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3
🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04889287Phase 1Completed

Competing Products

20 competing products in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
35
esomeprazole + placeboAstraZenecaPre-clinical
26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mgMerckPhase 2
27
Erenumab + PlaceboAmgenPhase 1
29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
43
DVS-233 SRPfizerPhase 3
40
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
40
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
40
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
40
Treatment A + Treatment B + Treatment CBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
26
Elinzanetant (BAY3427080)BayerPhase 1
26
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
37
BAY3427080BayerPhase 1
26